Circulating Biomarkers in Hypertrophic Cardiomyopathy

J Am Heart Assoc. 2022 Dec 6;11(23):e027618. doi: 10.1161/JAHA.122.027618. Epub 2022 Nov 16.


Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.

Keywords: biomarker; cardiac imaging; hypertrophic cardiomyopathy.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers / blood
  • Cardiomyopathy, Hypertrophic* / diagnosis
  • Cardiomyopathy, Hypertrophic* / physiopathology
  • Humans


  • Biomarkers